Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, Lasher J, Hughes G, Hu K, Shen G, Reséndiz KH, Giannone V, Beckers A. Petersenn S, et al. Among authors: hu k. J Clin Pharmacol. 2014 Nov;54(11):1308-17. doi: 10.1002/jcph.326. Epub 2014 May 24. J Clin Pharmacol. 2014. PMID: 24800725 Clinical Trial.
Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
Petersenn S, Unger N, Hu K, Weisshaar B, Zhang Y, Bouillaud E, Reséndiz KH, Wang Y, Mann K. Petersenn S, et al. Among authors: hu k. J Clin Pharmacol. 2012 Jul;52(7):1017-27. doi: 10.1177/0091270011408727. Epub 2011 Jun 14. J Clin Pharmacol. 2012. PMID: 21673137 Clinical Trial.
Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
Petersenn S, Hu K, Maldonado M, Zhang Y, Lasher J, Bouillaud E, Wang Y, Mann K, Unger N. Petersenn S, et al. Among authors: hu k. Clin Ther. 2012 Mar;34(3):677-88. doi: 10.1016/j.clinthera.2012.01.015. Epub 2012 Feb 24. Clin Ther. 2012. PMID: 22364824 Clinical Trial.
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
Petersenn S, Farrall AJ, De Block C, Melmed S, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao A, Ruffin M, Hermosillo Reséndiz K, Hughes G, Hu K, Barkan A. Petersenn S, et al. Among authors: hu k. Pituitary. 2014 Apr;17(2):132-40. doi: 10.1007/s11102-013-0478-0. Pituitary. 2014. PMID: 23529827 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.
Wolin EM, Hu K, Hughes G, Bouillaud E, Giannone V, Resendiz KH. Wolin EM, et al. Among authors: hu k. Cancer Chemother Pharmacol. 2013 Aug;72(2):387-95. doi: 10.1007/s00280-013-2202-1. Epub 2013 Jun 14. Cancer Chemother Pharmacol. 2013. PMID: 23765178 Free PMC article. Clinical Trial.
Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
Chen X, Shen G, Jiang J, Liu H, Hu K, Darstein C, Lasher J, Hu P. Chen X, et al. Among authors: hu k, hu p. Clin Ther. 2014 Aug 1;36(8):1196-210. doi: 10.1016/j.clinthera.2014.06.006. Epub 2014 Jul 8. Clin Ther. 2014. PMID: 25012727 Free article. Clinical Trial.
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM; Pasireotide Acromegaly Study Group. Petersenn S, et al. Among authors: hu k. J Clin Endocrinol Metab. 2010 Jun;95(6):2781-9. doi: 10.1210/jc.2009-2272. Epub 2010 Apr 21. J Clin Endocrinol Metab. 2010. PMID: 20410233 Clinical Trial.
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B. Kvols LK, et al. Among authors: hu k. Endocr Relat Cancer. 2012 Sep 14;19(5):657-66. doi: 10.1530/ERC-11-0367. Print 2012 Oct. Endocr Relat Cancer. 2012. PMID: 22807497 Clinical Trial.
6,343 results